# A Phase 2 Study of Farnesyl Transferase Inhibitor (R115777, Tipifarnib) in Patients With Refractory or Relapsed Acute Myeloid Leukemia.

> **NCT00354146** · PHASE2 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 252 (actual)

## Conditions studied

- Leukemia, Nonlymphocytic, Acute

## Interventions

- **DRUG:** tipifarnib (R115777)

## Key facts

- **NCT ID:** NCT00354146
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-04
- **Primary completion:** —
- **Final completion:** 2003-07
- **Target enrollment:** 252 (ACTUAL)
- **Last updated:** 2011-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00354146

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00354146, "A Phase 2 Study of Farnesyl Transferase Inhibitor (R115777, Tipifarnib) in Patients With Refractory or Relapsed Acute Myeloid Leukemia.". Retrieved via AI Analytics 2026-08-23 from https://api.ai-analytics.org/clinical/NCT00354146. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*